2 months: see Contraindications ... see full labeling. History of drug-induced immune thrombocytopenia with use of trimethoprim and/or sulfonamides. Megaloblastic anemia due to folate deficiency.

See Contraindications. Hypertensive crisis with MAOIs. Increased risk of serotonin syndrome with other serotonergic drugs (eg, SSRIs, SNRIs, tricyclic antidepressants, tramadol, bupropion ...

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has updated the U.S. Prescribing Information for CAMZYOS ...

Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindications Updated U.S ...

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA ... expanding patient eligibility by reducing contraindications. CAMZYOS is the first and only ...